Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

100%(1 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

Phase 3Large-scale testing

1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(1)

Detailed Status

Active, not recruiting1

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (50.0%)

Phase 31 (50.0%)

Trials by Status

active_not_recruiting133%

completed133%

withdrawn133%

Recent Activity

1 active trials

Showing 3 of 3

completedphase_1

A Gene Transfer Study for Hemophilia A

NCT03003533

withdrawnphase_3

Study of a Gene Therapy Treatment for Hemophilia A

NCT06297486

active_not_recruiting

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

NCT03432520

Clinical Trials (3)

Showing 3 of 3 trials

NCT03003533Phase 1

A Gene Transfer Study for Hemophilia A

Completed

NCT06297486Phase 3

Study of a Gene Therapy Treatment for Hemophilia A

Withdrawn

NCT03432520

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type: GENETIC
Total Trials: 3